MLH1 Gene as Cancer Drug Target and Biomarker (G128308)

Target Name: MRPL55

NCBI ID: G128308

MRPL55

MLH1 Gene as Cancer Drug Target and Biomarker

MRPL55 (MutL homolog 55) is a gene that encodes a protein known as MLH1 (MutL homolog 1). MLH1 is a member of the MSL/LMH (MutL homolog) family, which is characterized by the presence of a single transmembrane domain and a variable region that includes multiple conserved secondary structure domains.

The MLH1 protein is involved in the repair of DNA double-strand breaks in the context of homologous recombination (HR) during DNA replication. DNA double-strand breaks can occur due to various mechanisms, including exposure to mutagenic agents, endogenous double-strand break repair systems, or errors in DNA replication. In the context of HR, the MLH1 protein is essential for the efficient repair of double-strand breaks.

The MRPL55 gene has been identified as a potential drug target in cancer therapy. Cancer cells have a high rate of DNA double-strand break formation, which can lead to the development of genetic instability, mutations, and epigenetic alterations. Therefore, targeting DNA repair processes in cancer cells could be an effective strategy for the development of new anti-cancer drugs.

The MLH1 protein is a key player in the DNA repair pathway, and its dysfunction has been implicated in the development of various types of cancer. For example, studies have shown that MLH1-deficient mice have an increased susceptibility to radiation-induced DNA double- strand breaks and are less able to recover from DNA damage. Additionally, overexpression of MLH1 has been shown to enhance the sensitivity of cancer cells to chemotherapy drugs.

The MRPL55 gene has also been found to be significantly upregulated in various types of cancer, including breast, ovarian, and colorectal cancers. This increase in gene expression may indicate that MLH1 is involved in the development and progression of these diseases. Therefore, targeting the MRPL55 gene could be an effective way to develop new cancer therapies that specifically target this protein.

In addition to its potential as a drug target, MRPL55 may also be a biomarker for cancer diagnosis and monitoring. The over-expression of MLH1 has been shown to be associated with the development of various types of cancer, including breast and ovarian cancers. Therefore , measuring the expression of MLH1 in cancer cells or tissue could be an effective way to diagnose or monitor the progression of cancer.

The MRPL55 gene is also conserved across various species, which suggests that it may have evolved under different selective pressures. This conservation may indicate that MLH1 has important functions in the biology of different organisms, including humans. Therefore, studying the function of MLH1 in human cancer cells could provide valuable insights into the underlying mechanisms of cancer development and progression.

In conclusion, MRPL55 is a gene that has the potential to be a drug target or biomarker in cancer therapy. The MLH1 protein is involved in the repair of DNA double-strand breaks, which is critical for the efficient development and progression of cancer. The MLH1 protein is involved in the repair of DNA double-strand breaks, which is critical for the efficient development and progression of cancer. over-expression of MLH1 has been implicated in the development of various types of cancer, including breast and ovarian cancers. Therefore, targeting the MRPL55 gene could be an effective way to develop new cancer therapies that specifically target this protein. Additionally, MRPL55 may also be a biomarker for cancer diagnosis and monitoring. Further studies are needed to fully understand the role of MLH1 in cancer biology and its potential as a drug target or biomarker.

Protein Name: Mitochondrial Ribosomal Protein L55

The "MRPL55 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL55 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets